Search Results
10
Everything
Search Filters
Organization
Collegium Pharmaceutical, Inc.
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
April 01, 2025 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham...
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
March 27, 2025 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its...
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
March 17, 2025 07:00 ET
|
Collegium Pharmaceutical, Inc.
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of...
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
March 10, 2025 18:57 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its...
Collegium to Participate in Upcoming Investor Conferences
March 04, 2025 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor...
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
February 27, 2025 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue...
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
February 13, 2025 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the...
Collegium Appoints Nancy S. Lurker to its Board of Directors
February 05, 2025 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4,...
Collegium Provides 2025 Financial Guidance and Business Update
January 08, 2025 08:00 ET
|
Collegium Pharmaceutical, Inc.
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435...
Collegium to Participate in Upcoming Investor Conferences
November 12, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...